First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) — Net Asset Momentum
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) recorded a net asset momentum of -4.5% as of December 2024, with net assets of $391.60 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See First Tracks Biotherapeutics, Inc. Ordin (TRAXV) liquidity interval to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Net Asset Momentum (2023–2024)
This chart tracks First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's year-over-year net asset growth across 2 annual reporting periods from 2023 to 2024. The most recent momentum reading is -4.5%, with net assets of $391.60 Million USD as of December 2024. Read First Tracks Biotherapeutics, Inc. Ordin (TRAXV) total liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the complete annual net asset history for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024, covering 2 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see how much is First Tracks Biotherapeutics, Inc. Ordin worth.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | $391.60 Million | $441.89 Million | $50.30 Million | ▼ -4.5% |
| 2023 | $409.85 Million | $444.11 Million | $34.26 Million | — |